HER2-CAR

HER2-CAR refers to a chimeric antigen receptor (CAR) therapy targeting the Human Epidermal Growth Factor Receptor 2 (HER2). In the specific context of research from the University of Southern California, this involves a novel approach for glioblastoma (GBM) where glioblastoma stem cells (GSCs) are reprogrammed in situ into myeloid-like cells that express a HER2-specific CAR. This construct is uniquely regulated by a focused ultrasound (FUS)-inducible promoter, allowing for precise spatiotemporal control of CAR activity. This "fratricide" strategy aims to overcome the immunosuppressive tumor microenvironment and the blood-brain barrier by turning the tumor's own driver cells into therapeutic agents that target HER2-positive GBM cells.

Other names

FUS-inducible HER2-CARfocused ultrasound-controlled HER2-CAR